Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis
Aim: 20 mg of vonoprazan (VPZ20) is recommended in most countries to treat erosive esophagitis (EE). Whether other doses of vonoprazan, such as 5 mg (VPZ5), 10 mg (VPZ10), 20 mg (VPZ20), and 40 mg (VPZ40) are more effective is unknown. Materials & methods: Three databases were electronically...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2023-07-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: |
| _version_ | 1797776514775777280 |
|---|---|
| author | Jie He Yuanyuan Gao Ge Bai Jie Wang Yongshun Sun |
| author_facet | Jie He Yuanyuan Gao Ge Bai Jie Wang Yongshun Sun |
| author_sort | Jie He |
| collection | DOAJ |
| description | Aim: 20 mg of vonoprazan (VPZ20) is recommended in most countries to treat erosive esophagitis
(EE). Whether other doses of vonoprazan, such as 5 mg (VPZ5), 10 mg (VPZ10), 20 mg (VPZ20), and
40 mg (VPZ40) are more effective is unknown. Materials & methods: Three databases were electronically
searched to identify studies published before November 2021. Network meta-analysis was performed
using STATA 14.0. Results: VPZ20 and VPZ40 were comparable to PPI, VPZ5 and VPZ10 in 4- and 8-week
healing rates, and this was also detected in patients with refractory EE. All regimens resulted in similar
treatment-emergent adverse events (TEAEs). However, VPZ40 ranked first for healing rate and TEAEs;
however, VPZ20 ranked worst for TEAEs. Conclusion: Different doses of VPZ are comparable in efficacy
and safety, but VPZ40 may be best in both effectiveness and safety. |
| first_indexed | 2024-03-12T22:51:07Z |
| format | Article |
| id | doaj.art-7fb6df4ac0694450868f1c4bfa86b769 |
| institution | Directory Open Access Journal |
| issn | 2042-6313 |
| language | English |
| last_indexed | 2024-03-12T22:51:07Z |
| publishDate | 2023-07-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj.art-7fb6df4ac0694450868f1c4bfa86b7692023-07-20T10:27:33ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132023-07-0110.57264/cer-2022-0165Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitisJie He0https://orcid.org/0009-0002-2108-9131Yuanyuan Gao1https://orcid.org/0009-0002-8611-8861Ge Bai2Jie Wang3Yongshun Sun4https://orcid.org/0000-0002-6410-3004Gastrology/Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200000, ChinaApartment of Mental disease/Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200000, Shanghai, ChinaOncology/Shanxi University of Traditional Chinese Medicine, Taiyuan, Shanxi, 030000, ChinaGastrology/Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200000, ChinaGastrology/Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200000, ChinaAim: 20 mg of vonoprazan (VPZ20) is recommended in most countries to treat erosive esophagitis (EE). Whether other doses of vonoprazan, such as 5 mg (VPZ5), 10 mg (VPZ10), 20 mg (VPZ20), and 40 mg (VPZ40) are more effective is unknown. Materials & methods: Three databases were electronically searched to identify studies published before November 2021. Network meta-analysis was performed using STATA 14.0. Results: VPZ20 and VPZ40 were comparable to PPI, VPZ5 and VPZ10 in 4- and 8-week healing rates, and this was also detected in patients with refractory EE. All regimens resulted in similar treatment-emergent adverse events (TEAEs). However, VPZ40 ranked first for healing rate and TEAEs; however, VPZ20 ranked worst for TEAEs. Conclusion: Different doses of VPZ are comparable in efficacy and safety, but VPZ40 may be best in both effectiveness and safety.erosive esophagitisgastroesophageal reflux diseasenetwork meta-analysisproton-pump inhibitorsvonoprazan |
| spellingShingle | Jie He Yuanyuan Gao Ge Bai Jie Wang Yongshun Sun Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis Journal of Comparative Effectiveness Research erosive esophagitis gastroesophageal reflux disease network meta-analysis proton-pump inhibitors vonoprazan |
| title | Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis |
| title_full | Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis |
| title_fullStr | Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis |
| title_full_unstemmed | Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis |
| title_short | Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis |
| title_sort | network meta analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis |
| topic | erosive esophagitis gastroesophageal reflux disease network meta-analysis proton-pump inhibitors vonoprazan |
| work_keys_str_mv | AT jiehe networkmetaanalysisofmultipledosesofvonoprazanforthetreatmentoferosiveesophagitis AT yuanyuangao networkmetaanalysisofmultipledosesofvonoprazanforthetreatmentoferosiveesophagitis AT gebai networkmetaanalysisofmultipledosesofvonoprazanforthetreatmentoferosiveesophagitis AT jiewang networkmetaanalysisofmultipledosesofvonoprazanforthetreatmentoferosiveesophagitis AT yongshunsun networkmetaanalysisofmultipledosesofvonoprazanforthetreatmentoferosiveesophagitis |